Theravance Biopharma, Inc. Quarterly Deferred Tax Assets, Gross in USD from Q4 2013 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Theravance Biopharma, Inc. quarterly Deferred Tax Assets, Gross history and growth rate from Q4 2013 to Q4 2024.
  • Theravance Biopharma, Inc. Deferred Tax Assets, Gross for the quarter ending December 31, 2024 was $452M, a 0.96% increase year-over-year.
Deferred Tax Assets, Gross, Quarterly (USD)
Deferred Tax Assets, Gross, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 $452M +$4.29M +0.96% Dec 31, 2024 10-K 2025-03-07
Q4 2023 $447M +$6.55M +1.49% Dec 31, 2023 10-K 2025-03-07
Q4 2022 $441M -$46M -9.44% Dec 31, 2022 10-K 2024-03-01
Q4 2021 $487M +$15M +3.17% Dec 31, 2021 10-K 2023-03-01
Q4 2020 $472M +$58M +14% Dec 31, 2020 10-K 2022-02-28
Q4 2019 $414M +$45.8M +12.4% Dec 31, 2019 10-K 2021-02-26
Q4 2018 $368M +$325M +760% Dec 31, 2018 10-K 2020-02-27
Q4 2017 $42.8M +$13.9M +48.4% Dec 31, 2017 10-K 2019-02-28
Q4 2016 $28.8M +$1.4M +5.12% Dec 31, 2016 10-K 2018-02-28
Q4 2015 $27.4M +$8.25M +43% Dec 31, 2015 10-K 2017-03-01
Q3 2015 $28M +$10.9M +63.7% Sep 30, 2015 10-Q 2015-11-12
Q2 2015 $24.3M +$10.2M +72.3% Jun 30, 2015 10-Q 2015-08-13
Q1 2015 $22.2M Mar 31, 2015 10-Q 2015-05-13
Q4 2014 $19.2M -$164M -89.5% Dec 31, 2014 10-K 2016-03-11
Q3 2014 $17.1M Sep 30, 2014 10-Q 2014-11-12
Q2 2014 $14.1M Jun 30, 2014 10-Q 2014-11-12
Q4 2013 $183M Dec 31, 2013 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.